Stay updated with breaking news from Tumor Characterization. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NCCN Guidelines® for clinicians and patients now recommend the use of FES PET for ER+ positive disease under certain circumstances during the systemic staging workup of patients with recurrent... | May 24, 2023
(1) GE Healthcare to scale Zionexa's FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18), used as an adjunct to biopsy for the detection of estrogen receptor (ER) positive lesions to help inform treatment selection for patients with recurrent or metastatic breast cancer Aims to make Cerianna available to 75% of metastatic breast cancer patients in the U.S. by 2023 Acquisition demonstrates GE Healthcare's commitment to its precision health vision and builds additional pipeline of oncology and neurology tracers to help physicians personalize treatment GE Healthcare today announced ...
GE Healthcare to scale Zionexa’s FDA-approved PET imaging agent, Cerianna (fluoroestradiol F-18), used as an adjunct to biopsy for the detection of estrogen receptor (ER) positive lesions to help inform treatment selection for patients with recurrent or metastatic breast cancer Aims to make Cerianna available to 75% of metastatic breast cancer patients in the U.S. by 2023 Acquisition demonstrates GE Healthcare’s commitment to its precision health vision and builds additional pipeline of oncology and neurology tracers to help physicians personalize treatment 6 May 2021 – GE Healthcare to...